Macular degeneration, particularly age-related macular degeneration, is a leading cause of vision loss worldwide. This condition affects the central part of the retina, known as the macula, which is ...

New treatments for dry macular degeneration are helping slow vision loss, and researchers are testing therapies that may restore sight. Here’s what to know. Dry age-related macular degeneration is the ...

A new federally funded research effort in Rochester is aiming to tackle one of the biggest gaps in treating age-related macular degeneration — stopping vision loss before it starts. Researchers at ...

Researchers have developed a light-activatable prodrug nanomedicine for age-related macular degeneration (AMD) therapy. Through the intravenous injection of the nanomedicine and application of light ...

Add Yahoo as a preferred source to see more of our stories on Google. Current treatments sometimes fail to help people with "wet" age-related macular degeneration -- and researchers now think they ...

RetinAI Medical, a Swiss developer of software for accelerating retinal disease R&D, has joined the Ryan Initiative for Macular Research, a non-profit consortium working on defining optimal biomarkers ...

Macular degeneration (MD) is characterised by the progressive breakdown of the macula, the portion of the retina responsible for sharp, central vision, leading to visual distortion or loss.

Macular degeneration and macular dystrophy are eye conditions affecting the center of the retina. Although they share overlapping symptoms, their root causes and treatments differ. Macular ...

At least 20 million Americans ages 40 and older have age-related macular degeneration, and the threat posed by the vision-robbing condition will only grow larger as the population ages. Despite the ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...